JP6820278B2 - 抗Ｐｒｅ−Ｓ１ ＨＢＶ抗体 - Google Patents

抗Ｐｒｅ−Ｓ１ ＨＢＶ抗体 Download PDF

Info

Publication number
JP6820278B2
JP6820278B2 JP2017560539A JP2017560539A JP6820278B2 JP 6820278 B2 JP6820278 B2 JP 6820278B2 JP 2017560539 A JP2017560539 A JP 2017560539A JP 2017560539 A JP2017560539 A JP 2017560539A JP 6820278 B2 JP6820278 B2 JP 6820278B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
variable region
chain variable
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017560539A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018519804A (ja
JP2018519804A5 (cg-RX-API-DMAC7.html
Inventor
ジャンファ スイ，
ジャンファ スイ，
ダン リー，
ダン リー，
ウェンフイ リー，
ウェンフイ リー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huahui Health Ltd
Original Assignee
Huahui Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huahui Health Ltd filed Critical Huahui Health Ltd
Publication of JP2018519804A publication Critical patent/JP2018519804A/ja
Publication of JP2018519804A5 publication Critical patent/JP2018519804A5/ja
Priority to JP2020116317A priority Critical patent/JP7304320B2/ja
Application granted granted Critical
Publication of JP6820278B2 publication Critical patent/JP6820278B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017560539A 2015-05-22 2016-05-23 抗Ｐｒｅ−Ｓ１ ＨＢＶ抗体 Active JP6820278B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020116317A JP7304320B2 (ja) 2015-05-22 2020-07-06 抗Ｐｒｅ－Ｓ１ ＨＢＶ抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015079534 2015-05-22
CNPCT/CN2015/079534 2015-05-22
PCT/CN2016/082985 WO2016188386A1 (en) 2015-05-22 2016-05-23 Anti-Pre-S1 HBV Antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020116317A Division JP7304320B2 (ja) 2015-05-22 2020-07-06 抗Ｐｒｅ－Ｓ１ ＨＢＶ抗体

Publications (3)

Publication Number Publication Date
JP2018519804A JP2018519804A (ja) 2018-07-26
JP2018519804A5 JP2018519804A5 (cg-RX-API-DMAC7.html) 2019-06-27
JP6820278B2 true JP6820278B2 (ja) 2021-01-27

Family

ID=57392535

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017560539A Active JP6820278B2 (ja) 2015-05-22 2016-05-23 抗Ｐｒｅ−Ｓ１ ＨＢＶ抗体
JP2020116317A Active JP7304320B2 (ja) 2015-05-22 2020-07-06 抗Ｐｒｅ－Ｓ１ ＨＢＶ抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020116317A Active JP7304320B2 (ja) 2015-05-22 2020-07-06 抗Ｐｒｅ－Ｓ１ ＨＢＶ抗体

Country Status (10)

Country Link
US (3) US20180094047A1 (cg-RX-API-DMAC7.html)
EP (2) EP3978521A1 (cg-RX-API-DMAC7.html)
JP (2) JP6820278B2 (cg-RX-API-DMAC7.html)
KR (1) KR102770671B1 (cg-RX-API-DMAC7.html)
CN (3) CN113527470B (cg-RX-API-DMAC7.html)
ES (1) ES2896275T3 (cg-RX-API-DMAC7.html)
HK (1) HK1243429A1 (cg-RX-API-DMAC7.html)
MA (1) MA42137A (cg-RX-API-DMAC7.html)
RU (1) RU2739955C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016188386A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102770671B1 (ko) 2015-05-22 2025-02-24 화후이 헬스 리미티드 항-Pre-S1 HBV 항체
WO2019204462A2 (en) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
JP7454855B2 (ja) * 2018-12-21 2024-03-25 国立大学法人広島大学 抗ｐｒｅＳ１抗体およびその用途
WO2021013135A1 (en) * 2019-07-20 2021-01-28 Huahui Health Ltd. A method of treating hbv infection by using anti-pre-s1 hbv antibodies
JP2024525184A (ja) * 2021-06-15 2024-07-10 アピットバイオ， インク． Ｂ型肝炎ウイルスｐｒｅＳ１抗原の肝細胞受容体結合部位に特異的に結合するヒト抗体及びその用途
WO2023039243A2 (en) * 2021-09-13 2023-03-16 Achelois Biopharma, Inc. Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use
CN116568808A (zh) * 2021-10-19 2023-08-08 北京三诺佳邑生物技术有限责任公司 特异性结合乙型肝炎病毒表面抗原pre-S1的抗体及其应用
CN114685663B (zh) * 2022-04-07 2023-09-08 西南大学 一种抗胆固醇依赖性细胞溶素的抗体及其应用
CN117304308A (zh) * 2022-06-20 2023-12-29 华辉安健（北京）生物科技有限公司 抗乙型肝炎病毒的抗体及其制备和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
CA2041772A1 (en) * 1990-05-11 1991-11-12 Larry T. Mimms Monoclonal antibodies to pres2 and pres1 polypeptide of the hepatitis b viral envelope
ATE207119T1 (de) * 1992-11-06 2001-11-15 Sandoz Ltd Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
KR100345463B1 (ko) 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
CN1216914C (zh) * 2000-05-17 2005-08-31 韩国科学技术研究院 对hbv表面抗原pre－s1具有特异性的人源化抗体
KR100423614B1 (ko) * 2001-05-16 2004-03-22 주식회사유한양행 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
EP1281761A1 (en) * 2001-07-27 2003-02-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Hepatitis B virus pre-S1 derived synthetic polypeptides and their use thereof.
US7601351B1 (en) * 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
CN1733798B (zh) * 2005-08-12 2012-07-04 上海贺普生物科技有限公司 乙型肝炎病毒表面l蛋白相关肽
WO2011045079A1 (en) * 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
CN109354623B (zh) * 2012-04-25 2022-06-24 华辉安健（北京）生物科技有限公司 乙肝肝炎病毒功能性受体的组成以及相关应用
KR102770671B1 (ko) 2015-05-22 2025-02-24 화후이 헬스 리미티드 항-Pre-S1 HBV 항체

Also Published As

Publication number Publication date
US10544205B2 (en) 2020-01-28
JP2020171311A (ja) 2020-10-22
CN107614525A (zh) 2018-01-19
CN117247944A (zh) 2023-12-19
EP3298038A4 (en) 2019-04-24
WO2016188386A1 (en) 2016-12-01
EP3978521A1 (en) 2022-04-06
CN113527470A (zh) 2021-10-22
US20180148496A1 (en) 2018-05-31
CN113527470B (zh) 2023-08-25
US11485774B2 (en) 2022-11-01
RU2017145085A3 (cg-RX-API-DMAC7.html) 2020-01-23
EP3298038B1 (en) 2021-08-04
MA42137A (fr) 2021-04-07
EP3298038A1 (en) 2018-03-28
US20180094047A1 (en) 2018-04-05
ES2896275T3 (es) 2022-02-24
KR102770671B1 (ko) 2025-02-24
RU2739955C2 (ru) 2020-12-30
KR20180009780A (ko) 2018-01-29
JP7304320B2 (ja) 2023-07-06
US20220275060A9 (en) 2022-09-01
JP2018519804A (ja) 2018-07-26
CN107614525B (zh) 2021-07-06
HK1243429A1 (zh) 2018-07-13
US20200109186A1 (en) 2020-04-09
RU2017145085A (ru) 2019-06-24

Similar Documents

Publication Publication Date Title
JP7304320B2 (ja) 抗Ｐｒｅ－Ｓ１ ＨＢＶ抗体
KR102573257B1 (ko) 섬유증의 치료를 위한 항-fam19a5 항체의 용도
CN111320693B (zh) 抗EphA4抗体
KR20180012245A (ko) 다가 b형 간염 바이러스 항원 결합 분자 및 그의 용도
AU2021273240A1 (en) Anti-tigit antibody and preparation method and application thereof
KR20140108520A (ko) CD1d에 대한 항체
KR102656738B1 (ko) 항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체 및 이의 사용 방법
JP2021518761A (ja) 配列類似性１９、メンバーａ５抗体を有する抗ファミリー及びその使用方法
CN107074963A (zh) 抑制血管内皮脂肪酶的酶活性的人源化单克隆抗体
JP2022517216A (ja) 組換え抗ヒトｐｄ－１抗体およびその用途
WO2022141378A1 (zh) 一种抗pd-1的单域抗体
CA3192254A1 (en) Antibody specifically bound to glycosylated ceacam5
CN116262787B (zh) 一种抗人lag-3单克隆抗体及其制备方法和应用
TWI904172B (zh) 抗hbv抗體及使用方法
WO2025101747A1 (en) Methods and compositions for treatment of pulmonary hypertension
KR20240022546A (ko) 항il-36r 항체 및 그의 사용
WO2020156539A1 (en) Anti-fgf19 antibodies
CN120882746A (zh) 结合至nkg2a和pd-l1的药剂及其用途
TW202436338A (zh) Nkg2a結合劑及其用途
CN115975020A (zh) 靶向sars-cov-2s蛋白的抗原结合蛋白及其应用
TW202204396A (zh) 抗hbv抗體及使用方法
CN118660905A (zh) 针对sars相关冠状病毒的中和抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200706

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201211

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210104

R150 Certificate of patent or registration of utility model

Ref document number: 6820278

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20231016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231016

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250